Marksans Pharma Ltd. reported their Q2 and H1 FY24 financial results, showing revenue growth of 17.4% YoY in Q2 and 16.3% YoY in H1, with increased demand and market share gains across key regions. Operating revenue was Rs. 531.2 cr. in Q2 and Rs. 1,031.3 cr. in H1, with EBITDA of Rs. 113.9 cr. in Q2 and Rs. 215.9 cr. in H1.